Updated coverage on one of our favorite NASDAQ stocks coming tomorrow at the bell

Updated coverage on one of our favorite NASDAQ stocks coming tomorrow at the bell

Good day everyone,

The stock market indices are giving investors a reason to be optimistic and to invest. The NASDAQ, DJIA and the S&P 500 are hitting record levels. As we have previously stated, we believe the American economy has many catalysts driving its momentum.

The mega-cap tech companies, Apple, Google, Amazon, Microsoft, and Facebook (FB hit a market valuation of $1T), along with big-cap chip winners such as Nvidia (NVDA) and AMD (AMD), fueled the S&P 500 and Nasdaq composite to record highs, while the Dow Jones set a record close last week.

Governmental spending, and spending yet to come, coupled with consumer spending are driving the economy. According to the Bureau of Labor Statistics, the current unemployment rate has fallen to 5.9%, not as low as pre-pandemic levels but not a crisis level either. Higher pay levels across the spectrum of jobs are giving consumers more to spend.

In another indication the economy may be booming, 115 traditional IPOs, collecting $40.7 billion, were completed in Q2. It was the highest number of deals in a quarter since the third quarter of 2000, when 139 companies went public. The $40.7 billion is the biggest amount raised by new issues since the fourth quarter of 1999, when 154 companies, valued at $46.5 billion, listed their stock.

Recent comments by the FED indicate they are willing to stand by the status quo. One of the most important economic factors controlled by the FED is interest rates. Cheap money available to businesses and consumers is crucial to the development of a robust economy.

We want to talk about one of our favorite biopharma companies that recently saw their share price retreat. This company has had nothing but positive events in its clinical trials, but a couple cynical viewpoints were published that impacted the company’s market value.

Some of you will already know who we are talking about. We want to give our perspective of events happening at this company, particularly in their current clinical trial process. This company has had virtually no discouraging press before but had a couple pot shots taken toward it last week.

Stay tuned and stay informed.

The Traders News Group

Privacy Policy and Disclaimer